Wall Street brokerages expect Solid Biosciences Inc (NASDAQ:SLDB) to announce earnings per share of ($0.62) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.66). Solid Biosciences posted earnings per share of ($0.55) in the same quarter last year, which indicates a negative year-over-year growth rate of 12.7%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Solid Biosciences will report full-year earnings of ($2.85) per share for the current fiscal year, with EPS estimates ranging from ($3.05) to ($2.68). For the next financial year, analysts expect that the business will post earnings of ($2.06) per share, with EPS estimates ranging from ($2.17) to ($1.91). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05.
A number of research analysts have recently issued reports on SLDB shares. Chardan Capital upgraded shares of Solid Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $7.50 to $10.00 in a research report on Friday, August 16th. Citigroup set a $6.00 price target on shares of Solid Biosciences and gave the stock a “hold” rating in a research report on Thursday, May 16th. Goldman Sachs Group downgraded shares of Solid Biosciences from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Tuesday, May 14th. Zacks Investment Research upgraded shares of Solid Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, ValuEngine upgraded shares of Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $8.21.
In related news, Director Life Sciences Maste Perceptive acquired 2,822,581 shares of the stock in a transaction dated Thursday, July 25th. The stock was bought at an average price of $4.65 per share, for a total transaction of $13,125,001.65. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 31.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in SLDB. Geode Capital Management LLC increased its stake in Solid Biosciences by 25.4% during the 4th quarter. Geode Capital Management LLC now owns 168,090 shares of the company’s stock valued at $4,504,000 after purchasing an additional 34,060 shares in the last quarter. Emory University lifted its stake in Solid Biosciences by 335.0% in the 1st quarter. Emory University now owns 298,887 shares of the company’s stock valued at $2,750,000 after buying an additional 230,173 shares in the last quarter. Virtu Financial LLC purchased a new stake in Solid Biosciences in the 1st quarter valued at approximately $186,000. Bank of New York Mellon Corp lifted its stake in Solid Biosciences by 35.7% in the 4th quarter. Bank of New York Mellon Corp now owns 56,703 shares of the company’s stock valued at $1,520,000 after buying an additional 14,925 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Solid Biosciences in the 1st quarter valued at approximately $325,000. Institutional investors own 60.06% of the company’s stock.
NASDAQ:SLDB traded down $0.05 during mid-day trading on Thursday, hitting $9.03. 456,928 shares of the company’s stock were exchanged, compared to its average volume of 719,732. The firm has a market capitalization of $329.27 million, a P/E ratio of -4.01 and a beta of 2.07. Solid Biosciences has a fifty-two week low of $4.32 and a fifty-two week high of $54.54. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 0.08. The company has a 50 day simple moving average of $5.87 and a 200-day simple moving average of $7.88.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Read More: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.